Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: A single-center experience
- PMID: 39164118
- DOI: 10.1111/1756-185X.15295
Effect of the Janus kinase inhibitor tofacitinib in the treatment of juvenile scleroderma: A single-center experience
References
REFERENCES
-
- Li SC. Scleroderma in children and adolescents: localized scleroderma and systemic sclerosis. Pediatr Clin N Am. 2018;65(4):757‐781. doi:10.1016/j.pcl.2018.04.002
-
- McGaugh S, Kallis P, de Benedetto A, Thomas RM. Janus kinase inhibitors for treatment of morphea and systemic sclerosis: a literature review. Dermatol Ther. 2022;35(6):e15437. doi:10.1111/dth.15437
-
- Wang W, Bhattacharyya S, Marangoni RG, et al. The JAK/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib. J Scleroderma Relat Disord. 2020;5(1):40‐50. doi:10.1177/2397198319865367
-
- Moriana C, Moulinet T, Jaussaud R, Decker P. JAK inhibitors and systemic sclerosis: a systematic review of the literature. Autoimmun Rev. 2022;21(10):103168. doi:10.1016/j.autrev.2022.103168
-
- George R, George A, Kumar TS. Update on management of morphea (localized scleroderma) in children. Indian Dermatol Online J. 2020;11(2):135‐145. doi:10.4103/idoj.IDOJ_284_19
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
